Published • loading... • Updated
Merck tops third-quarter estimates as Keytruda, Gardasil outperform
Merck also raised its adjusted profit outlook as Keytruda QLEX brought in $830 million and Gardasil sales rose 14%, both above estimates.
- On Thursday, Merck reported third-quarter revenue of $18.1 billion, topping the $17.3 billion estimate, and raised its full-year adjusted earnings forecast to $2.77–$2.82 per share.
- Growth was driven by Keytruda sales of $8.6 billion, beating analyst expectations, and Gardasil vaccine sales of about $2 billion, rebounding after weak China demand last year hampered performance.
- Keytruda Qlex, the newer injectable formulation, generated $830 million in sales, while pulmonary arterial hypertension drug Winrevair surged 94% to $694 million, exceeding Wall Street expectations.
- Merck narrowed its 2026 revenue guidance to $66.8–$67.3 billion, incorporating a one-time $400 million charge, equivalent to 12 cents per share, from a licensing agreement with Chinese drugmaker SciBrunch.
- To offset anticipated generic competition for Keytruda after patents expire in 2028, Merck is positioning Keytruda Qlex as a cornerstone of its growth strategy and pursuing strategic acquisitions to diversify its portfolio.
Insights by Ground AI
11 Articles
11 Articles
The pharmaceutical company Merck, known as MSD in Brazil, released this Thursday (29) profit above expected for the third quarter, driven by strong demand for its highly successful cancer drug, Keytruda, and for its HPV vaccine, Gardasil. The American pharmaceutical company registered revenue of US$ 18.1 billion in the third quarter, exceeding the average estimate of US$ 17.3 billion of analysts, according to LSEG data. The adjusted profit was U…
·Rio de Janeiro, Brazil
Read Full Article
Merck tops third-quarter estimates as Keytruda, Gardasil outperform
·London, United Kingdom
Read Full Article
Merck Boosts Profit Forecast as Key Medicines Top Estimates
·New York, United States
Read Full Article
Coverage Details
Total News Sources11
Leaning Left2Leaning Right1Center4Last UpdatedBias Distribution57% Center
Bias Distribution
- 57% of the sources are Center
57% Center
L 29%
C 57%
14%
Factuality
To view factuality data please Upgrade to Premium
